Crescendo Biologics (a biopharmaceutical company based in Cambridge, UK) is discovering and developing potent, highly differentiated Humabody® VH therapeutics in Oncology. By leveraging the advantages of the Humabody format, along with substantial in-house expertise in engineering multispecific products, Crescendo is able to rapidly construct numerous multispecific combinations of Humabody product building blocks in a highly flexible manner. The company is using this to efficiently explore and identify optimal formats for engaging therapeutically valuable targets in a way that is fundamentally different than those using whole antibodies. This approach offers a unique way of unlocking new biology through simultaneous engagement of multiple synergistic pathways. In this way, Crescendo is pursuing novel product opportunities, through both in-house development and strategic partnerships in both multispecific immuno-oncology modulators and HDCs (Humabody Drug Conjugates) and would be delighted to discuss areas of common interest with potential new partners.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.